Small molecule drugs - Optimizing DNA damaging agent-based therapeutics

Current Opinion in Pharmacology

Volumn 12, Issue 4, 2012, Pages 398-402

  Hartley, John A ^a   Hochhauser, Daniel ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AURISTATIN DERIVATIVE; BENDAMUSTINE; BRENTUXIMAB VEDOTIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUDARABINE; GEFITINIB; IFOSFAMIDE; IRINOTECAN; MAYTANSINOID DERIVATIVE; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLOBENZODIAZEPINE DERIVATIVE; RITUXIMAB; SG 2000; SG 2057; SG 2202; SG 2285; SJG 136; TRABECTEDIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DNA DAMAGE; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EWS CHOP GENE; FUN CHOP GENE; FUSION GENE; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SOFT TISSUE SARCOMA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIAZEPINONES; DIOXOLES; DNA; DNA DAMAGE; HUMANS; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; PYRROLES; TETRAHYDROISOQUINOLINES;

EID: 84864973134     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.03.008     Document Type: Review

References (34)

1. J. Valle, H. Wasan, D.H. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, S. Madhusudan, T. Iveson, S. Hughes, and S.P. Pereira ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
2. J.A. Ledermann, H. Gabra, G.C. Jayson, V.J. Spanswick, G.J. Rustin, M. Jitlal, L.E. James, and J.A. Hartley Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer Clin Cancer Res 16 2010 4899 4905
3. T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J.L. Raoul, S. Gourgou-Bourgade, and C. de la Fouchardière Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
4. M. D'Incalci, and C.M. Galmarini A review of Trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 2010 2157 2163
5. P. Schoffski, M. Taron, J. Jimeno, F. Grosso, R. Sanfilipo, P.G. Casali, A. Le Cesne, R.L. Jones, J.Y. Blay, and A. Poveda Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study Eur J Cancer 47 2011 1006 1012
6. A. Italiano, A. Laurand, A. Laroche, P. Casali, R. Sanfilipo, A. Le Cesne, I. Judson, J.Y. Blay, I. Ray-Coquard, and B. Bui ERCC5/XPG, ERCC1 and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma Cancer 117 2011 3445 3456
7. B. Massuti, M. Cobo, C. Camps, M. Domine, M. Provencio, V. Alberola, N. Vinolas, R. Rosell, M. Taron, and V. Gutierrez-Calderon Trabectedin in patients with advanced non-small cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum Lung Cancer 2012 Epub ahead of print
8. F. Grosso, R. Sanfilippo, E. Virdis, C. Piovesan, P. Collini, P. Dileo, C. Morosi, J.C. Tercero, J. Jimeno, and M. D'Incalci Trabectedin in myxoid liposarcomas (MLS): a long term analysis of a single-institution series Ann Oncol 20 2009 1439 1444
9. C. Forni, M. Minuzzo, E. Virdis, E. Tamborini, M. Simone, M. Tavecchio, E. Erba, F. Grosso, A. Gronchi, and P. Aman Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors Mol Cancer Ther 8 2009 449 457
10. P.J. Grohar, L.B. Griffin, C. Yeung, Q.R. Chen, Y. Pommier, C. Khanna, J. Khan, and L.J. Helman Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewings sarcoma cells Neoplasia 13 2011 145 153
11. G. Germano, R. Frapolli, M. Simone, M. Tavecchio, E. Erba, S. Pesce, F. Pasqualini, F. Grosso, R. Sanfilippo, and P.G. Casali Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells Cancer Res 70 2010 2235 2244
12. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, F.M. Muggia, E. Pujade-Lauraine, A.S. Lisyanskaya, A.N. Makhson, and J. Rolski Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
13. A. Poveda, I. Vergote, S. Tjulandin, B. Kong, M. Roy, S. Chan, E. Filipczyk-Cisarz, H. Hagberg, S.B. Kaye, and N. Colombo Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Ann Oncol 22 2011 39 48
14. S.B. Kaye, N. Colombo, B.J. Monk, S. Tjulandin, B. Kong, M. Roy, S. Chan, E. Filipczyk-Cisarz, H. Hagberg, and I. Vergote Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 2011 49 58
15. M.J. Rummel, and S.A. Gregory Bendamustine's emerging role in the management of lymphoid malignancies Semin Hematol 48 Suppl. 1 2011 S24 S36
16. B.S. Kahl, N.L. Bartlett, J.P. Leonard, L. Chen, K. Ganjoo, M.E. Williams, M.S. Czuczman, K.S. Robinson, R. Joyce, R.H. van der Jagt, and B.D. Cheson Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study Cancer 116 2010 106 114
17. J.W. Friedberg, J.M. Vose, J.L. Kelly, F. Young, S.H. Bernstein, D. Peterson, L. Rich, S. Blumel, N.K. Proia, and J. Liesveld The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Blood 117 2010 2807 2812
18. N. Fowler, B.S. Kahl, P. Lee, J.V. Matous, A.F. Cashen, S.A. Jacobs, J. Letzer, B. Amin, M.E. Williams, and S. Smith Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study J Clin Oncol 29 2011 3389 3395
19. K. Fischer, P. Cramer, R. Busch, S. Stilgenbauer, J. Bahlo, C.D. Schweighofer, S. Böttcher, P. Staib, M. Kiehl, and M.J. Eckart Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group J Clin Oncol 29 2011 3559 3566
20. L.M. Leoni, and J.A. Hartley Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity Semin Hematol 48 Suppl. 1 2011 S12 S23
21. J.A. Hartley, V.J. Spanswick, N. Brooks, P.H. Clingen, P.J. McHugh, D. Hochhauser, R.B. Pedley, L.R. Kelland, M.C. Alley, and R. Schultz SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity: Part 1: cellular pharmacology, in vitro and initial in vivo antitumour activity Cancer Res 64 2004 6693 6699
22. J.A. Hartley The development of pyrrolobenzodiazepines as antitumor agents Expert Opin Investig Drugs 20 2011 733 744
23. D. Hochhauser, T. Meyer, V.J. Spanswick, J. Wu, P.H. Clingen, M. Cobb, L. Gumbrell, R.H. Begent, J.A. Hartley, and D. Jodrell Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors Clin Cancer Res 15 2009 2140 2147
24. I. Puzanov, W. Lee, A.P. Chen, M.W. Calcutt, D.L. Hachey, W.L. Vermeulen, V.J. Spanswick, C.-Y. Liao, J.A. Hartley, J.D. Berlin, and M.L. Rothenberg Phase I, pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors Clin Cancer Res 17 2011 3794 3802
25. J.A. Hartley, A. Hamaguchi, M. Suggitt, S.J. Gregson, D.E. Thurston, and P.W. Howard DNA interstrand cross-linking and in vivo antitumour activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 Investig New Drugs 2012 Epub ahead of print
26. J.A. Hartley, A. Hamaguchi, M. Coffils, C. Martin, M. Suggitt, Z. Chen, S.J. Gregson, L.A. Masterson, A.C. Tiberghien, and J.A. Hartley SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer pro-drug that cross-links DNA and exerts highly potent antitumor activity Cancer Res 70 2010 6849 6858
27. A. Gualberto Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies Expert Opin Investig Drugs 21 2012 205 216
28. B. Friedmann, M. Caplin, J.A. Hartley, and D. Hochhauser Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839) Clin Cancer Res 10 2004 6476 6486
29. K. Dittmann, C. Mayer, B. Fehrenbacher, M. Schaller, U. Raju, L. Milas, D.J. Chen, R. Kehlbach, and H.P. Rodemann Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase J Biol Chem 280 2005 31182 31189
30. M. Kriegs, U. Kasten-Pisula, T. Rieckmann, K. Holst, J. Saker, J. Dahm-Daphi, and E. Dikomey The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining DNA Repair (Amst) 9 2010 889 897
31. E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, and G. Bodoky Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
32. T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade, M.T. Seymour, R.H. Wilson, S. Idziaszczyk, R. Harris, D. Fisher, and S.L. Kenny MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
33. Z. Shi, X.X. Peng, I.W. Kim, S. Shukla, Q.S. Si, R.W. Robey, S.E. Bates, T. Shen, C.R. Ashby Jr., and L.W. Fu Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res 67 2007 11012 11020
34. L. Dahan, A. Sadok, J.L. Formento, J.F. Seitz, and H. Kovacic Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines Br J Pharmacol 158 2009 610 620